Myotonic syndrome
MONDO:001612061 clinical trials for this condition and its sub-types, 11 tagged with Myotonic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myotonic syndrome
-
Myotonic dystrophy 56 trials · 57 incl. sub-types
8 sub-types
- Myotonic dystrophy type 1 45 trials Sub-types →
- Myotonic dystrophy type 2 11 trials
- Congenital myotonic dystrophy 9 trials
- Childhood-onset Steinert myotonic dystrophy 2 trials
- Juvenile-onset Steinert myotonic dystrophy 2 trials
- Adult-onset Steinert myotonic dystrophy 0 trials
- Late-onset Steinert myotonic dystrophy 0 trials
- Myotonic cataract 0 trials
-
Nondystrophic myotonia 4 trials
-
Potassium-aggravated myotonia 0 trials
3 sub-types
- Acetazolamide-responsive myotonia 0 trials
- Myotonia fluctuans 0 trials
- Myotonia permanens 0 trials
Most studied deeper sub-types
-
Experimental drug AOC 1001 tested for Long-Term safety in rare muscle disease
Disease control CompletedThis study is a follow-up to an earlier trial, testing the long-term safety and effects of a drug called AOC 1001 in adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. 37 participants who completed the first study received multiple doses of AOC 1001 by IV infu…
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a Muscle-Relaxing drug offer Long-Term relief for children with myotonia?
Disease control CompletedThis trial evaluates the long-term safety and effectiveness of mexiletine in children aged 6 to 18 with myotonic disorders, conditions where muscles have trouble relaxing after contraction. Participants, who previously completed a study of mexiletine, receive the drug for about 8…
Sponsor: Lupin Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control CompletedThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug AOC 1001 tested for rare muscle disease
Disease control CompletedThis study tested a new drug called AOC 1001 in 39 adults with myotonic dystrophy type 1, a genetic muscle disorder. Participants received either the drug or a placebo by IV infusion. The goal was to check safety and how the drug moves through the body. Results will help decide i…
Phase 1/2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug PGN-EDODM1 tested for muscle disease
Disease control CompletedThis early-stage trial tested a single dose of the drug PGN-EDODM1 in 24 adults with myotonic dystrophy type 1, a genetic muscle disorder. The main goal was to check safety and how the body handles the drug. The study is complete, but results are not yet available.
Phase 1 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC